Targeting B cell dysregulation with emerging therapies in autoimmune demyelinating disorders.
Curr Opin Neurobiol
; 77: 102643, 2022 12.
Article
en En
| MEDLINE
| ID: mdl-36244128
ABSTRACT
The depletion of B cells has proven to be beneficial in the treatment of autoimmune demyelinating disorders. The high efficacy of these therapies has highlighted the importance of B cells in autoimmunity and prompted investigations into specific B cell subsets that may be aberrant. Recently, a rise in the trialling of alternative B cell-targeting therapies that inhibit targets such as Bruton's tyrosine kinase, interleukin-6 receptor and fragment crystallisable neonatal receptor has also been observed. These agents interfere with specific dysregulated functions of B cells in contrast to the broad removal of many B cell subsets with depletion agents. The therapeutic benefit of these emerging agents will help delineate the contributions of B cells in demyelinating disorders and holds great potential for future treatment.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Enfermedades Autoinmunes
/
Enfermedades Desmielinizantes
Idioma:
En
Revista:
Curr Opin Neurobiol
Asunto de la revista:
BIOLOGIA
/
NEUROLOGIA
Año:
2022
Tipo del documento:
Article